Olympus (7733) Q2 2026 earnings summary

Executive summary

• Medium-term plan targets gradual revenue growth: 3% in year one, 4% in year two, and 5% in year three, aiming to reach or exceed mid-single-digit market growth rates over time.

• Organizational restructuring underway, including a reduction of approximately 2,000 positions and a shift to a division-led operating model to enhance efficiency and accountability.

• Focus on innovation-driven growth, with new product launches (e.g., EDOF scopes, EVIS X1, Bronchoscope, OLYSENSE) and external partnerships to drive performance.

• Achieved strong growth in emerging markets by expanding market reach and access capabilities, despite declines in main business divisions.

• The Orthopedic Business was classified as a discontinued operation from the six months ended September 30, 2024.

Financial highlights

• Margin improvement targeted at 100 basis points per year, aiming for 19% adjusted operating profit by FY2029, with aspirations to reach 20% or higher over time.

• 2Q FY2026 revenue: ¥247.8B, up 4% year-over-year after FX adjustment; adjusted operating profit: ¥37.4B, down 9% year-over-year; adjusted operating margin at 15.1%.

• 6-month revenue: ¥454.4B, down 4.2% year-over-year; adjusted operating profit: ¥50.6B, down 40.6% year-over-year.

• One-time expenses related to restructuring (JPY 30 billion over two years) and FDA remediation (JPY 10 billion to be resolved this fiscal year) are included in guidance.

• SG&A ratio remains high but is expected to improve with ongoing cost reduction efforts.

Outlook and guidance

• FY2026 revenue forecast: ¥998.0B, flat year-over-year, with 3% growth after FX adjustment; adjusted operating profit forecast: ¥157.0B (15.7% margin), down 9% year-over-year after FX adjustment.

• Profit attributable to owners of parent forecast: ¥94.0B; EPS: ¥85; annual dividend forecast: ¥30/share, up ¥10/share; ¥50B share buyback planned.

• Guidance is intentionally conservative to rebuild credibility, with upside potential if product launches and market recoveries outperform.

• No inorganic growth (M&A, JVs, distribution deals) is included in the forecast; such opportunities would accelerate growth if realized.

• Forward-looking statements are subject to risks from global economic and trade policy uncertainties.